Forte Biosciences’ $40 Million Public Offering

Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the deal. Forte Biosciences, a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering of…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Ambrogio Visconti

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here